10-Q/A 1 form10qa1033108.htm form10qa1033108.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q /A1

(Mark One)
P QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended:  March 31, 2008

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
For the transition period from to
Commission file number: 0-12968

InMedica Development Corporation
(Exact name of small business issuer as specified in its charter)

UTAH
87-0397815
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)

825 North 300 West, Suite N132
Salt Lake City, Utah 84103
(Address of principal executive offices)

(801) 521-9300
(Issuer’s telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes P No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 

Large accelerated filer
Accelerated filer
Non-accelerated filer
P Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes o No P

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 18,629,493 shares of $.001 par value common stock as of May 12, 2008


 
 

 

The Company hereby amends and restates in its entirety, the Consolidated Balance Sheet of the Company filed with Form 10Q for the period ended March 31, 2008 to include comparative data for December 31, 2007, as shown below.

INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET


ASSETS
           
   
As of
   
As of
 
   
March 31,
   
December 31,
 
   
2008
   
2007
 
   
(Unaudited)
   
(audited)
 
             
CURRENT ASSETS:
           
     Cash & cash equivalents
  $ 11,969     $ 2,706  
    Prepaid expenses and other
    200       200  
                 
          Total current assets
    12,169       2,906  
                 
EQUIPMENT AND FURNITURE, at cost,
               
  Less accumulated depreciation of
               
  $254,947 and $254,856 respectively
    274       365  
                 
          Total assets
  $ 12,443     $ 3,271  


See notes to consolidated financial statements

 
 

 

INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET (Continued)

LIABILITIES AND STOCKHOLDERS' EQUITY
           
   
As of
   
As of
 
   
March 31,
   
December 31,
 
   
2008
   
2007
 
   
(Unaudited)
   
(audited)
 
             
CURRENT LIABILITIES:
           
     Related party consulting fees payable
  $ 84,000     $ 78,000  
     Accounts payable
    21,232       5,503  
     Accrued payroll
    12,000       -  
     Accrued interest
    20,362       16,495  
     Related party royalty payable
    83,333       73,333  
     Preferred stock dividend payable
    51,069       49,177  
      Current portion of long term debt
    140,000       60,617  
                 
     Total current liabilities
    411,996       283,125  
                 
LONG TERM LIABILITIES
               
      Long term convertible promissory note
    85,033       140,000  
                 
TOTAL LIABILITIES
    497,029       423,125  
                 
MINORITY INTEREST
    (217,169 )     (191,668 )
                 
STOCKHOLDERS' EQUITY:
               
     Preferred stock, 10,000,000 shares authorized;
               
       Series A preferred stock, cumulative and
               
       convertible, $4.50 par value,
               
       1,000,000 shares designated,
               
       21,016 shares issued and outstanding
    94,573       94,573  
     Common stock, $.001 par value;
               
       40,000,000 shares authorized,
               
       18,629,493 issued and outstanding
    18,629       18,629  
       Additional paid-in capital
    8,426,839       8,426,839  
       Accumulated deficit
    (8,807,458 )     (8,768,227 )
                 
          Total stockholders equity
    (267,417 )     (228,186 )
                 
          Total liabilities and stockholders' equity
  $ 12,443     $ 3,271  


See notes to consolidated financial statements

 
 

 

Item 6.                    Exhibits:
 
(31.1)                      Sarbanes-Oxley Section 302 Certification – Ralph Henson
(31.2)                      Sarbanes- Oxley Section 302 Certification- Richard Bruggeman
(32.1)                      Sarbanes-Oxley Section 906 Certification

 
 

 



SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized.

INMEDICA DEVELOPMENT CORPORATION


/s/ Ralph Henson
By  Ralph Henson, President


/s/ Richard Bruggeman
By  Richard Bruggeman, Treasurer


Date:   September  26 , 2008


 
 

 

EXHIBIT INDEX - INMEDICA DEVELOPMENT CORPORATION
FORM 10Q /A1 – MARCH 31, 2008

EXHIBIT NUMBER
DESCRIPTION
 
(31.1)                          Sarbanes-Oxley Section 302 Certification – Ralph Henson
(31.2)                          Sarbanes- Oxley Section 302 Certification- Richard Bruggeman
(32.1)                          Sarbanes-Oxley Section 906 Certification